Anatomical Shoulder Domelock System Study

Sponsor
Zimmer Biomet (Industry)
Overall Status
Recruiting
CT.gov ID
NCT03312465
Collaborator
(none)
73
6
155.1
12.2
0.1

Study Details

Study Description

Brief Summary

The objectives of this study are to confirm safety and performance of the Anatomical Shoulder Domelock System when used in hemi or total shoulder arthroplasty by analysis of standard scoring systems, radiographs and adverse event records.

Detailed Description

This study is a multicenter, prospective and retrospective, non-controlled PMCF study involving orthopaedic surgeons skilled in hemi and total shoulder arthroplasty procedures. A minimum of six study centers will be involved and a total number of 73 implants will be included into the study.

Study Design

Study Type:
Observational
Anticipated Enrollment :
73 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Anatomical Shoulder™ Domelock System A Multicenter, Prospective and Retrospective, Non-Controlled Post-Market Clinical Follow-up Study
Actual Study Start Date :
Sep 28, 2017
Anticipated Primary Completion Date :
Aug 31, 2025
Anticipated Study Completion Date :
Aug 31, 2030

Arms and Interventions

Arm Intervention/Treatment
AS Domelock System Subjects

Subjects that receive the Anatomical Shoulder Domelock System

Device: AS Domelock System
Hemi or Total Shoulder Arthroplasty

Outcome Measures

Primary Outcome Measures

  1. Implant Survivorship [10 Years]

    The primary endpoint of this study is defined by the survival of the implant at 10 years which is based on removal or intended removal of the prosthesis and will be determined using Kaplan Meier method.

Secondary Outcome Measures

  1. Clinical Performance [5 Years]

    The secondary endpoint is defined by the performance of the Anatomical Shoulder Domelock System at 5 years, which is assessed by the Constant and Murley score. The Constant and Murley score is a 100-point functional shoulder assessment tool in which higher scores reflect increased function. The subjective variables are pain (15 points) and function (activities of daily living - sleep, work, recreation/sport; 20 points), for a total of 35 points. The objective variables are active range of motion (clinician assessment; 40 points) and strength (25 points), for a total of 65 points.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient is 18-80 years of age, inclusive

  • Patient is skeletally mature

  • Patient is suffering from severe shoulder pain and disability requiring unilateral or bilateral HSA or TSA based on physical exam and medical history

  • Patient has failed conservative treatment

  • Patient meets at least one of the following indications:

  • Advanced wear and tear of the shoulder joint resulting from degenerative, posttraumatic or rheumatoid arthritis if bone stock is adequate.

  • Avascular necrosis

  • Conditions consequent to earlier operations

  • Optional use in revision: in some medical conditions (e.g., early revision when adequate bone stock exists), the surgeon may opt to use primary implants in a revision procedure.

Additional criteria for retrospective patients:
  • patient has been implanted with the Domelock system before site initiation visit.

  • information available must include at minimum demographic information, the operative report and details of the device implanted.

Exclusion Criteria:
  • Patient is unwilling or unable to give consent or to comply with the follow-up program

  • Patients who have any condition which would in the judgement of the Investigator place the patient at undue risk or interfere with the study. Any patient who is institutionalized, or is a known drug abuser, a known alcoholic or anyone who cannot understand what is required of them

  • Patient is known to be pregnant or breastfeeding

  • Patient meets at least one of the contraindications:

  • Patient's physical conditions that would impair adequate implant support and/or prevent the use of an appropriately sized implant, e.g., previous surgery, insufficient quality or quantity of bone, neuromuscular compromise or vascular deficiency in the affected limb in sufficient degree to endanger the success of the intervention e.g., absence of musculoligamentous supporting structures, joint neuropathy or other conditions that may lead to inadequate skeletal fixation

  • Signs of infection

  • Severe instability secondary to advanced loss of osteochondral structure

  • Charcot's shoulder (neuroarthropathy)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universitaire Ziekenhuizen Leuven Leuven Belgium
2 Krankenhaus Maria Hilf Daun Germany
3 HELIOS ENDO-Klinik Hamburg Hamburg Germany
4 Universitätsspital Basel Basel Switzerland
5 Univeritätklinik Bagrist Zürich Switzerland 8008
6 Royal Derby Hospital Derby United Kingdom DE22 3NE

Sponsors and Collaborators

  • Zimmer Biomet

Investigators

  • Study Director: Hassan Achakri, Clinical Operations Director Zimmer Biomet EMEA

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zimmer Biomet
ClinicalTrials.gov Identifier:
NCT03312465
Other Study ID Numbers:
  • CME2014-07E
First Posted:
Oct 17, 2017
Last Update Posted:
Jan 6, 2022
Last Verified:
Dec 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Zimmer Biomet
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 6, 2022